Drug Research
Takeda and PvP Biologics Announce Development Agreement around Novel Therapeutic for Celiac Disease
Takeda Pharmaceutical Company Limited and PvP Biologics, Inc announced a global agreement for the development of KumaMax, a novel enzyme designed to break down the immune-reactive parts of gluten in the stomach, thereby avoiding the painful symptoms and damage...
Drug Research
Marinus Pharma Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
Marinus Pharmaceuticals Inc , a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders announced that the U.S. FDA has granted Orphan Drug Designation to its CNS-selective GABAA modulator, ganaxolone, for the treatment...
Articles
Clinical research data sharing promises new cures and treatments
Clinical research generates extensive amounts of data, yet most of it is siloed or generally unavailable to a larger pool of willing potential researchers.
If this data were liberated to the masses, we would venture into a world of endless...
Drug Research
Glenmark Pharma gets USFDA approval for Tretinoin Capsules
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Tretinoin. Capsules, 10 mg, the generic version of Vesanoid Capsules, 10 mg, of Hoffmann La...
Drug Research
IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery
IBM Watson Health and Pfizer Inc announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's research in immuno-oncology, an approach to cancer treatment that uses the body's immune system to help fight cancer....
Drug Research
Global market will reach $26 billion by 2020, says GBI Research
The global market for drug delivery technologies will rise from $20 billion in 2015 to around $26 billion by 2020, according to business intelligence firm GBI Research. The company’s latest report states that the emergence of...
Drug Research
Neos Therapeutics Submits NDA for Amphetamine Extended-Release Liquid Suspension Drug Candidate, Amphetamine, for the Treatment of ADHD
Neos Therapeutics a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit hyperactivity disorder (ADHD), announced that it has submitted a NDA to the U.S. FDA for its Amphetamine...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















